ABILIFY MAINTENA 400mg

Resumen del producto

About ABILIFY MAINTENA 400mg

ABILIFY MAINTENA 400mg is a long‑acting injectable formulation of the antipsychotic drug aripiprazole. It is designed for the maintenance treatment of schizophrenia and bipolar disorder in adults. The medication is administered once a month by a qualified healthcare professional. The formulation delivers a steady release of aripiprazole over a 28‑day period, helping to maintain therapeutic drug levels and reduce the frequency of dosing compared with oral antipsychotics. The injection is given into the muscle of the buttock or thigh, and the procedure is typically performed in a clinical setting. Patients receiving ABILIFY MAINTENA 400mg should continue to attend regular follow‑up appointments to monitor efficacy and tolerability. The product is supplied in a pre‑filled syringe containing 400 mg of aripiprazole in a sterile solution. The medication is intended for use under the supervision of a prescribing clinician and should be stored at room temperature until administration.

Key Benefits & Uses

• Provides once‑monthly dosing, improving adherence to treatment.
• Maintains stable plasma concentrations of aripiprazole.
• Reduces the need for daily oral medication and associated compliance issues.

Active Ingredient & Action

The active ingredient is aripiprazole, a dopamine partial agonist that modulates dopamine and serotonin receptors in the brain. By acting on these neurotransmitter systems, aripiprazole helps to stabilize mood and reduce psychotic symptoms. The drug’s pharmacologic profile allows for a balanced effect on both positive and negative symptoms of schizophrenia and mood stabilization in bipolar disorder.

Important Notes

Patients should be monitored for potential side effects such as injection site reactions, changes in mood, or movement disorders. The medication should not be used in patients with known hypersensitivity to aripiprazole or any component of the formulation. It is essential to follow the prescribing information and to report any adverse events to a healthcare professional promptly. The injection must be administered by a trained clinician, and patients should not attempt self‑injection. Regular blood pressure and metabolic monitoring is recommended during long‑term treatment.